We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

OvaGene, Hitachi Collaborate on mRNA Biomarkers for Gynecological Cancers

By LabMedica International staff writers
Posted on 01 Oct 2014
Print article
Ovagene (Irvine, CA, USA), a molecular diagnostics firm, will collaborate with Hitachi Chemical Research Center (Irvine, CA, USA) to develop novel mRNA-based signatures for gynecological cancers. The collaboration aims to develop tests for the analysis of tumor mRNA within exosomes and microvessels in blood and vaginal fluids. Financial and other terms of the deal were not disclosed.

The agreement, which leverages Hitachi’s exosome technologies and OvaGene’s research, clinical validation, and translational expertise, focuses on the development of blood-based mRNA signatures to guide the selection of therapy and to monitor therapy response for ovarian cancer. The partners will also seek to identify novel mRNA signatures for diagnosing the early onset of ovarian or endometrial cancer in high-risk women, according to OvaGene spokespersons.

OvaGene reported that although early detection is the key to successfully treating ovarian and endometrial cancers, there currently are no simple, cost-effective, and reliable tests for early detection. Also lacking are approaches for quickly determining whether a specific therapy is effective for a patient.

William Ricketts, CSO of OvaGene, said, “These assays are developed to use blood or body fluid samples, making them easier to obtain from patients than surgical specimens.” He added that technologies such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) have resulted in less invasive methods of obtaining samples and can be used to develop robust and reproducible laboratory tests. “Less invasive sample collection can potentially increase the number of patients who will be tested, therefore increasing the number of cancer patients identified at an earlier stage of disease.”

Related Links:

Ovagene
Hitachi Chemical Research Center


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Automatic Nucleic Acid Extractor
GeneRotex 24

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more

Pathology

view channel
Image: The new AI tool can help beat brain tumors (Photo courtesy of Crystal Light/Shutterstock)

New AI Tool Classifies Brain Tumors More Quickly and Accurately

Precision in diagnosing and categorizing tumors is essential for delivering effective treatment to patients. Currently, the gold standard for identifying various types of brain tumors involves DNA methylation-based... Read more